Degenerative Cervical Myelopathy Patients Often Have Severe Residual Paresthesia
By Lori Solomon HealthDay Reporter
MONDAY, March 11, 2024 -- Just under half of patients (45 percent) with degenerative cervical myelopathy (DCM) show severe residual paresthesia one year after surgery, according to a study published online in the March 15 issue of Spine.
Koji Tamai, M.D., from Osaka Metropolitan University in Japan, and colleagues examined the incidence of residual paresthesias after surgery for DCM and analyzed the impact of these symptoms on clinical outcomes and patient satisfaction. The analysis included data from 187 patients who underwent laminoplasty for DCM.
The researchers found that 86 of 187 patients had severe residual paresthesia at one year postoperatively. There was a significant association between preoperative patient-oriented pain scale scores and postoperative residual paresthesia. Patients with severe postoperative residual paresthesia showed significantly smaller improvements in quality of life and myelopathy versus patients with no or mild residual paresthesia in a mixed-effect model. Furthermore, residual paresthesia was significantly associated with lower treatment satisfaction, independent of improvements in myelopathy and quality of life (adjusted odds ratio, 2.50).
"In patients who experience higher preoperative pain, multidisciplinary approaches for residual paresthesia, including medications for neuropathic pain, might lead to greater clinical satisfaction," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Etiology of Spinal Cord Injury Affects QOL Outcomes After Bladder Surgery
WEDNESDAY, July 3, 2024 -- For patients undergoing urinary diversion for neurogenic bladder (NGB), the postoperative impact on urinary-related quality of life (UrQOL) is milder...
Perioperative Chemo Improves Progression-Free Survival in Pancreatic Cancer
TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant...
Few Patients With Positive Margins After Basal Cell Excision Have Recurrence
MONDAY, July 1, 2024 -- Among patients with incompletely excised basal cell carcinoma (BCC), only about 16 percent with positive histopathologic margins have clinical recurrence...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.